Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-23
2007-01-23
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S254030, C544S367000, C544S369000
Reexamination Certificate
active
10492250
ABSTRACT:
This invention relates to N-aroyl piperazine derivatives of formula (I), wherein: Y represents NR2; m represents 1, 2 or 3; p represents 0 or 1; X is O, S, C═O, SO2, or CH═CH—; Ar1is aryl, or a mono or bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; any of which may be optionally substituted; Ar2represents phenyl or a 5- or 6-membered heterocyclyl group containing 1 to 3 heteroatoms selected from N, O and S, wherein the phenyl heterocyclyl group is substituted by R1and further optional substituents; or Ar2represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing 1 to 4 heteroatoms selected from N, O and S; R1represents optionally substituted (C1-4)alkoxy, halo, optionally substituted (C1-6)alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S; R2represents hydrogen, optionally substituted (C1-4)alkyl, optionally substituted (C1-6)alkanoyl, optionally subtituted (C1-6)alkanoxycarbonyl or optionally substituted aryl(C1-6)alkyloxycarbonyl; and their use as orexin receptor-antagonists.
REFERENCES:
patent: 8-40999 (1996-02-01), None
patent: WO 98/57954 (1998-12-01), None
patent: WO 01/25219 (2001-04-01), None
patent: WO 01/96302 (2001-12-01), None
patent: WO 02/44172 (2002-06-01), None
patent: WO 02/089800 (2002-11-01), None
patent: WO 02/090355 (2002-11-01), None
Fujii et al. Chemical Abstracts, vol. 124, No. 34333, Abstract for JP 08040999 (1996).
Rodgers et al. Neuropeptides, vol. 36(5), p. 303-325 (2002).
Cai et al. Expert Opin. Ther. Patents, vol. 16, p. 631-646 (2006).
Langmead et al.Br. J. Pharmacol., 141: 340-346 (2004).
Porter et al.Bioorg. &Med. Chem. Lett., 11: 1907-1910 (2001).
Duxon et al.Psychopharmacology, 153: 203-209 (2001).
White et al.Peptides, 26: 2331-2338 (2005).
Ishii et al.Behav. Brain Res., 160: 11-24 (2005).
Ishii et al.Behav. Brain Res., 157: 331-341 (2005).
Ishii et al.Physiol. &Behav., 81: 129-140 (2004).
Smith et al.Neurosci. Lett., 341: 256-258 (2003).
Haynes et al.Regulatory Peptides, 104: 153-159 (2002).
Bingham et al.Pain, 92: 81-90 (2001).
Rodgers et al.Eur. J. Neurosci., 13: 1444-1452 (2001).
Smart et al.Br. J. Pharmacol., 132: 1179-1182 (2001).
Jones et al.Psychopharmacology, 153: 210-218 (2001).
Haynes et al.Regulatory Peptides, 96: 45-51 (2000).
Branch Clive Leslie
Johnson Christopher Norbert
Nash David John
Stemp Geoffrey
Bernhardt Emily
Kinzig Charles M.
McCarthy Mary E.
Sieburth Kathryn L.
SmithKline Beecham p.l.c.
LandOfFree
N -aroyl piperazine derivatives as orexin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N -aroyl piperazine derivatives as orexin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N -aroyl piperazine derivatives as orexin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3814076